7 Biggest Mid-Day Losers For Monday

shares declined 68.35 percent to $1.69 as the company reported top-line results from Phase 3 trial in adult focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint.

dropped 26.08 percent to $1.95.

shares fell 17.54 percent to $6.11 as the company reported that the independent data monitoring committee has recommended the continuation of ADAPT Phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma following interim data review.

shares dropped 16.14 percent to $22.44.

shares dropped 13.78 percent to $2.44 as the company said it struck a deal to acquire HS Infusion Holdings Inc. in a synergistic, transformational and accretive transactions with considerable gains for all stake holders. The company also announced a proposed stock offering for HS Infusion acquisition.

declined 14.62 percent to $8.88. DA Davidson downgraded Emerge Energy Services from Buy to Underperform.

shares slipped 12.66 percent to $6.80. Raymond James downgraded OraSure Technologies from Outperform to Market Perform.